FDA Expands Clearance for Agendia's MammaPrint | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia today said that the US Food and Drug Administration has cleared its MammaPrint breast cancer recurrence test for all ages.

Amsterdam-based Agendia said that it is the fourth FDA clearance for MammaPrint over the past three years. It also noted that MammaPrint has been approved in Europe for all ages since 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.